Breast Cancer Clinical Trial

Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) – Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

Summary

This is a cohort study of women with suspected or confirmed recurrent breast cancer, with accessible tumor by standard clinical biopsy, prior to starting a new therapy for recurrent metastatic disease. Study participants will be ascertained from the population of all persons greater than eighteen years of age receiving care at the clinical practices of the Rowan Breast Center (RBC) at the University of Pennsylvania. The overarching goal of this study is to identify the genetic and molecular markers of molecular evolution identified in patients who have progressed from a primary diagnosis of breast cancer to recurrent, metastatic disease. As an observational study, this study seeks to gather data regarding the molecular and genetic changes that a primary cancer undergoes as a patient's cancer recurs and ultimately progresses. We anticipate enrolling 600 women with recurrent breast cancer who meet eligibility requirements for this study. Participation in this study will include the following: a biopsy and blood collection, completion of the study questionnaire, an optional bone marrow aspiration, and repeat collection of blood, offer of a research biopsy and a optional bone marrow aspirate collection at each progression time point. The study participants' medical information will be updated and changes in disease status will be captured on a regular basis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically-confirmed breast cancer - based upon pathology report of the primary or metastatic diagnosis
Recurrent breast cancer (local, regional, or distant disease) - as determined by either clinical,radiological, or pathological evaluation
Willing to undergo or provide tissue from a recent biopsy of recurrent tumor for both clinical and research testing
Willing to undergo blood specimen collection
Age 18 or over and are able to give informed consent

Exclusion Criteria:

Non-metastatic breast cancer (stage I, II or III)
Anticoagulation that cannot be interrupted for the purpose of study evaluation (patients must have normal INR and PTT at the time of study biopsy)

Study is for people with:

Breast Cancer

Estimated Enrollment:

600

Study ID:

NCT02530008

Recruitment Status:

Recruiting

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Abramson Cancer Center of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States More Info
Angela DeMichele, MD
Contact
855-216-0098
[email protected]
Angela DeMichele, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

600

Study ID:

NCT02530008

Recruitment Status:

Recruiting

Sponsor:


Abramson Cancer Center of the University of Pennsylvania

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider